Comparative Pharmacology
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus FOCALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus FOCALIN.
DEXTROAMPHETAMINE SULFATE vs FOCALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
Dexmethylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations. The d-threo enantiomer of methylphenidate is responsible for the therapeutic activity.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
Initial 2.5-5 mg orally twice daily, increase by 2.5-10 mg/day weekly; max 20 mg twice daily.
None Documented
None Documented
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
2-3 hours in children and adults; 4-5 hours in adolescents (due to slower metabolism). Clinical context: t1/2 supports twice-daily dosing (immediate-release) for continuous therapeutic effect
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Renal: 80% (approximately 50% as unchanged drug, 30% as metabolites); Fecal: negligible
Category D/X
Category C
CNS Stimulant
CNS Stimulant